News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 29, 2024

Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

Author(s)Kirollos S. Hanna, PharmD, BCPS, BCOP, Hope Rugo, MD, Joyce O’Shaughnessy, MD

Dr. Rugo details her management strategy in regards to GI toxicities.

Episodes in this series

EP. 1 Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

EP. 1 Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

EP. 2 Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

EP. 2 Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

EP. 3 Outcomes from NATALEE and MonarchE

EP. 3 Outcomes from NATALEE and MonarchE

EP. 4 Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

EP. 4 Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

A panel of 4 experts on breast cancer

EP. 5 Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

A panel of 4 experts on breast cancer

EP. 6 Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients

A panel of 4 experts on breast cancer

EP. 7 Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

A panel of 4 experts on breast cancer

EP. 8 Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

A panel of 4 experts on breast cancer

EP. 9 Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

A panel of 4 experts on breast cancer

EP. 10 How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

A panel of 4 experts on breast cancer

EP. 11 Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

A panel of 4 experts on breast cancer

EP. 12 Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

A panel of 4 experts on breast cancer

EP. 13 ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

Video content above is prompted by the following question(s):

What specific strategies do you use for mitigating gastrointestinal toxicities associated with abemaciclib in the adjuvant setting?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

New Biomarker Signatures Reveal Lapatinib Resistance in HER2+ Breast Cancer: Ateequllah Hayat, PhD

BySabrina McCrear,Ateequllah Hayat, PhD

February 5th 2026

City St. George’s researcher Ateequllah Hayat, PhD, explains newly identified mechanisms behind lapatinib resistance in HER2-positive breast cancer.

New Molecular Drivers of HER2 Breast Cancer Resistance: A Q&A With Ateequllah Hayat, PhD

BySabrina McCrear,Ateequllah Hayat, PhD

February 4th 2026

Breast cancer screening | Image credit: lordn - stock.adobe.com

AI-Supported Mammography Caught More Cancers During Screening

ByJulia Bonavitacola

January 29th 2026

Dr Debra Patt

Patient Advocacy Helps Shape Clinical Trial Approvals, Policy Decisions: Debra Patt, MD, PhD, MBA, MPH

ByBrooke McCormick,Debra Patt, MD, PhD, MBA, MPH

January 16th 2026

Dr Debra Patt

Patient Perspectives Drive More Relevant, Feasible Clinical Research: Debra Patt, MD, PhD, MBA, MPH

ByBrooke McCormick,Debra Patt, MD, PhD, MBA, MPH

January 13th 2026

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

How Do GLP-1 Agonists Fit Into Stroke Care?

Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD

Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making

5 Things to Know About the Oral GLP-1 Era

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.

Alt Text

Alt Text